Physicians' Academy for Cardiovascular Education

Meeting Impression | Managing Diabetes & CVD: Is epigenetics a new way forward?

August 26, 2017 - ESC
August 26, 2017 - ESC

In this educational program, which was held at the ESC Congress 2017 in Barcelona, Spain, epigenetic regulation of gene expression in patients at high CV risk with diabetes was reviewed

Summary | Insights from the first trials in epigenetics in human: What is the way forward?

August 26, 2017 - Prof. Stephen Nicholls (Adelaide, Australia)
August 26, 2017 - Prof. Stephen Nicholls (Adelaide, Australia)

Prof Nicholls shared some insights from the first human trials on epigenetic approaches to treat CVD. More specifically, he summarized the findings from the first trials with apabetalone.

Summary | Promise of epigenetic modulation as a target in atherosclerotic patients

August 26, 2017 - Prof. Erik Stroes (Amsterdam, The Netherlands)
August 26, 2017 - Prof. Erik Stroes (Amsterdam, The Netherlands)

Prof Stroes explained epigenetics and epigenetic modulation. Moreover, he summarized data from studies with apabetalone, a BET inhibitor, and the first trial results with apabetalone.

Summary | Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

August 26, 2017 - Prof. Kausik Ray (London, UK)
August 26, 2017 - Prof. Kausik Ray (London, UK)

This summary by Prof Ray gives insight in the high CV risk in patiens with diabetes. Treatment options and testing of these drugs in trials were discussed, including the new antidiabetic drugs, such as empagliflozin, and other novel agents, such as the PCSK9 inhibitor evolocumab.

Insights from the first trials in epigenetics in human: What is the way forward?

Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017
Lecture by Prof Stephen Nicholls held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

Promise of epigenetic modulation as a target in atherosclerotic patients

Aug. 26, 2017 - Barcelona, Spain - Erik SG Stroes, MD, Amsterdam, the Netherlands - PACE-CME symposium at ESC 2017
Lecture by Prof Erik Stroes held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

The Clinical Unmet need in the patient with Diabetes and ACS

Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017
Lecture by Prof Kausik Ray held at symposium on BET Inhibition: Managing high risk diabetes patient with cardiovascular disease: What works, and what else can we do?

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017

Managing Diabetes & CVD: Is epigenetics a new way forward?
Managing Diabetes & CVD: Is epigenetics a new way forward?